Onyx Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Onyx Pharmaceuticals, Inc.
The latest application submission news and highlights from the Pink Sheet’s US FDA Performance Tracker.
With goal dates for almost 40 novel drugs and biologics coming up in the second half of 2020 after a record number of first half approvals, even the pandemic looks unlikely to prevent another solid year for innovative drugs at US FDA.
At least another four investigational therapies will join the few that are already being fast-tracked at the European Medicines Agency.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
- Other Names / Subsidiaries
- Proteolix, Inc.